



14519 DETROIT AVENUE LAKEWOOD, OHIO 44107 PHONE (216) 521-4200

February 28, 1970

Amendment 13

U. S. Atomic Energy Commission
Division of Materials Licensing
Washington, D. C.

Gentlemen:

I request that AEC License No. 34-01197-01, issued to Lakewood Hospital Nuclear Medicine Department, be amended to include the use of Selenium 75 labeled Methionine for pancreas scanning in humans. Maximum dose - 250 μ C, maximum possession limit 3 mC.

I have been actively engaged in conducting scans for over six years. The preceptor statement indicates my participation in three pancreas scanning procedures under the supervision of a physician who is experienced in pancreas scanning.

I am prepared to submit annual summary reports regarding diagnostic accuracy of this procedure and the optimum pre-administration diet, if so directed.

Sincerely yours,

W. J. Fayen, M.D.
Director
Nuclear Medicine Department

WJF:mlf
Encl. - 3

MAR 6 1970

A24
B209220081 B20729
PDR FOIA
MIHALB2-310 PDR

14053

APPLICATION FOR BYPRODUCT MATERIAL LICENSE—MEDICAL
SUPPLEMENT A—PRECEPTOR STATEMENT

This page is to be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each. Back of page may be used for comments.

9. NAME AND ADDRESS OF APPLICANT PHYSICIAN (Include ZIP Code.)

William J. Fayen, M. D.

10. CLINICAL TRAINING AND EXPERIENCE OF PHYSICIAN NAMED IN ITEM 9 ABOVE

(A) ISOTOPE	(B) CONDITIONS DIAGNOSED OR TREATED	(C) No. Cases Observed (See 1 in key below)	(D) No. Cases Involving Personal Participation (See 2 in key below)
I-131	Diagnosis of thyroid function		
	Dilution studies		
	Excretion studies		
	Brain tumor localization		
	Scanning studies		
	Treatment of hyperthyroidism		
	Treatment of cardiac conditions		
P-32 Soluble	Treatment of polycythemia		
	Treatment of leukemia		
	Treatment of bone metastases		
	Tumor localization		
	Intracavitary treatment		
Au-198	Intracavitary treatment		
	Interstitial treatment		
	Scanning studies		
Cr-51	Blood determinations		
	Scanning studies		
Co-58 or Co-60	Diagnosis of pernicious anemia		
Co-60 I-192	Interstitial treatment		
	Intracavitary treatment		
Co-60 or Cs-137	Teletherapy treatment		
Sr-90	Treatment of superficial diseases of the eye		
Other Isotopes Use back of page	Selenium-75		3

Key to Column (C) and (D) above

1. Observation should consist of observing radioisotope administration techniques and discussion with preceptor the case histories to establish most appropriate diagnostic and/or therapeutic procedure, limitation, contraindications, etc.
2. Personal participation should consist of (a) supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation on dosage to be prescribed; (b) collaboration in calibration of the dose and the actual administration of the dose to the patient, including calculation of the radiation dose, related measurements, and plotting of data; and (c) adequate period of training to enable the physician to manage radioactive patients and to follow patients through diagnosis and/or the course of treatment.

11. DATES AND TOTAL NUMBER OF HOURS OF CLINICAL RADIOISOTOPE TRAINING

12. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF D. Bruce Sodee, M. D.

AT Hillcrest Hospital

(Institution) Name and Address

34-9739-1

(Byproduct Material License Number)

D. Bruce Sodee
4-20-63
(Signature of Preceptor)